The association between metabolic syndrome and colorectal neoplasm: Systemic review and meta-analysis

Journal of Clinical Gastroenterology

Volumn 47, Issue 1, 2013, Pages 33-44

  Jinjuvadia, Raxitkumar ^a   Lohia, Prateek ^a   Jinjuvadia, Chetna ^a   Montoya, Sergio ^a   Liangpunsakul, Suthat ^b,c  

^a WAYNE STATE UNIVERSITY   (United States)

^b INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^c RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

colorectal cancer; meta analysis; metabolic syndrome

Indexed keywords

COLORECTAL ADENOMA; COLORECTAL CANCER; COLORECTAL TUMOR; DISEASE ASSOCIATION; HUMAN; META ANALYSIS; METABOLIC SYNDROME X; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW;

CASE-CONTROL STUDIES; COHORT STUDIES; COLORECTAL NEOPLASMS; CONFIDENCE INTERVALS; EVIDENCE-BASED MEDICINE; HUMANS; METABOLIC SYNDROME X; RISK FACTORS; UNITED STATES;

EID: 84871557424     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3182688c15     Document Type: Review

References (50)

1. American Cancer Society. Cancer Facts & Figures. Atlanta: American Cancer Society; 2011.
2. Surveillance Epidemiology and End Results. 2011; Available at: http://seer. cancer. gov/statfacts/html/colorect. html#risk.
3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
4. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004;110:1245-1250.
5. Ervin RB. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003-2006. Natl Health Stat Rep. 2009;1-7.
6. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002; 287:356-359.
7. Cowey S, Hardy RW. The metabolic syndrome: a high-risk state for cancer? Am J Pathol. 2006;169:1505-1522.
8. Aleksandrova K, Boeing H, Jenab M, et al. Metabolic syndrome and risks of colon and rectal cancer: the European Prospective Investigation into Cancer and Nutrition Study. Cancer Prev Res (Phila). 2011;4:1873-1883.
9. Bowers K, Albanes D, Limburg P, et al. A prospective study of anthropometric and clinical measurements associated with insulin resistance syndrome and colorectal cancer in male smokers. Am J Epidemiol. 2006;164:652-664.
10. Liu CS, Hsu HS, Li CI, et al. Central obesity and atherogenic dyslipidemia in metabolic syndrome are associated with increased risk for colorectal adenoma in a Chinese population. BMC Gastroenterol. 2010;10:51.
11. Stocks T, Lukanova A, Bjorge T, et al. Metabolic factors and the risk of colorectal cancer in 580, 000 men and women in the metabolic syndrome and cancer project (Me-Can). Cancer. 2010;117:2398-2407.
12. Tsilidis KK, Brancati FL, Pollak MN, et al. Metabolic syndrome components and colorectal adenoma in the CLUE II cohort. Cancer Causes Control. 2010;21:1-10.
13. Alberti KG, Zimmer PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. 1. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic Med. 1998;15:539-553.
14. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabetic Med. 2006;23: 469-480.
15. Grundy SM, Brewer HB Jr, Cleeman JI, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109: 433-438.
16. Hogue CJ, Gaylor DW, Schulz KF. Estimators of relative risk for case-control studies. Am J Epidemiol. 1983;118:396-407.
17. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas. 1960;20:37-46.
18. Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-analyses. Available at: http://www. ohri. ca/programs/clinical-epidemiology/oxford. asp. Accessed December 10, 2011.
19. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-1558.
20. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50: 1088-1101.
21. Egger M, Davey Smith G, Schneider M, et al. Bias in metaanalysis detected by a simple, graphical test. BMJ. 1997; 315:629-634.
22. Ahmed RL, Schmitz KH, Anderson KE, et al. The metabolic syndrome and risk of incident colorectal cancer. Cancer. 2006;107:28-36.
23. Ashbeck EL, Jacobs ET, Martinez ME, et al. Components of metabolic syndrome and metachronous colorectal neoplasia. Cancer Epidemiol Biomarkers Prev. 2009;18:1134-1143.
24. Inoue M, Noda M, Kurahashi N, et al. Impact of metabolic factors on subsequent cancer risk: results from a large-scale population-based cohort study in Japan. Eur J Cancer Prev. 2009;18:240-247.
25. Kim MC, Kim CS, Chung TH, et al. MONW phenotype is associated with advanced colorectal adenoma in Korean men. Obesity (Silver Spring), 2011. DOI: 10. 1038/oby. 2011. 34.
26. Pelucchi C, Negri E, Talamini R, et al. Metabolic syndrome is associated with colorectal cancer in men. Eur J Cancer. 2010; 46:1866-1872.
27. Stocks T, Lukanova A, Johansson M, et al. Components of the metabolic syndrome and colorectal cancer risk; a prospective study. Int J Obes (Lond). 2008;32:304-314.
28. Sturmer T, Buring JE, Lee IM, et al. Metabolic abnormalities and risk for colorectal cancer in the physicians' health study. Cancer Epidemiol Biomarkers Prev. 2006;15: 2391-2397.
29. Hu NC, Chen JD, Lin YM, et al. Stepwise relationship between components of metabolic syndrome and risk of colorectal adenoma in a Taiwanese population receiving screening colonoscopy. J Formos Med Assoc. 2011;110:100-108.
30. Kang HW, Kim D, Kim HJ, et al. Visceral obesity and insulin resistance as risk factors for colorectal adenoma: a crosssectional, case-control study. Am J Gastroenterol. 2010;105: 178-187.
31. Kim JH, Lim YJ, Kim YH, et al. Is metabolic syndrome a risk factor for colorectal adenoma? Cancer Epidemiol Biomarkers Prev. 2007;16:1543-1546.
32. Morita T, Tabata S, Mineshita M, et al. The metabolic syndrome is associated with increased risk of colorectal adenoma development: the Self-Defense Forces health study. Asian Pac J Cancer Prev. 2005;6:485-489.
33. Kaneko R, Sato Y, An Y, et al. Clinico-epidemiologic study of the metabolic syndrome and lifestyle factors associated with the risk of colon adenoma and adenocarcinoma. Asian Pac J Cancer Prev. 2010;11:975-983.
34. Oh TH, Byeon JS, Myung SJ, et al. Visceral obesity as a risk factor for colorectal neoplasm. J Gastroenterol Hepatol. 2008;23:411-417.
35. Larsson SC, Wolk A. Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. Am J Clin Nutr. 2007;86:556-565.
36. Yuhara H, Steinmaus C, Cohen SE, et al. Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer? Am J Gastroenterol. 2011;106:1911-1921; quiz 1922.
37. Yamada K, Araki S, Tamura M, et al. Relation of serum total cholesterol, serum triglycerides and fasting plasma glucose to colorectal carcinoma in situ. Int J Epidemiol. 1998; 27:794-798.
38. Dai Z, Xu YC, Niu L. Obesity and colorectal cancer risk: a meta-analysis of cohort studies. World J Gastroenterol. 2007;13:4199-4206.
39. Giovannucci E. Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr. 2007;86:s836-s842.
40. Leu CM, Wong FH, Chang C, et al. Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways. Oncogene. 2003;22:7809-7818.
41. Aaronson SA. Growth factors and cancer. Science. 1991;254: 1146-1153.
42. Warren RS, Yuan H, Matli MR, et al. Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. J Biol Chem. 1996;271:29483-29488.
43. Guo YS, Narayan S, Yallampalli C, et al. Characterization of insulinlike growth factor I receptors in human colon cancer. Gastroenterology. 1992;102(pt 1):1101-1108.
44. Watkins LF, Lewis LR, Levine AE. Characterization of the synergistic effect of insulin and transferrin and the regulation of their receptors on a human colon carcinoma cell line. Int J Cancer. 1990;45:372-375.
45. Larsson SC, Giovannucci E, Wolk A. Diabetes and colorectal cancer incidence in the cohort of Swedish men. Diabetes Care. 2005;28:1805-1807.
46. Limburg PJ, Vierkant RA, Fredericksen ZS, et al. Clinically confirmed type 2 diabetes mellitus and colorectal cancer risk: a population-based, retrospective cohort study. Am J Gastroenterol. 2006;101:1872-1879.
47. Gunter MJ, Canzian F, Landi S, et al. Inflammation-related gene polymorphisms and colorectal adenoma. Cancer Epidemiol Biomarkers Prev. 2006;15:1126-1131.
48. Kim S, Keku TO, Martin C, et al. Circulating levels of inflammatory cytokines and risk of colorectal adenomas. Cancer Res. 2008;68:323-328.
49. Hodge DR, Hurt EM, FarrarWL. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer. 2005;41:2502-2512.
50. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer. 2009;9:361-371.